Literature DB >> 12006287

Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome.

Florian S Eichler1, Paul Wang, Robert J Wityk, Norman J Beauchamp, Peter B Barker.   

Abstract

Two cases of reversible posterior leukoencephalopathy syndrome were examined with proton MR spectroscopic imaging. Widespread metabolic abnormalities, consisting of increased choline and creatine levels and mildly decreased N-acetylaspartate, occurred in regions with both normal and abnormal MR imaging appearances. In one case for which proton MR spectroscopic imaging follow-up was available, all metabolite levels had returned to normal by 2 months. Proton MR spectroscopic imaging may be helpful for the diagnosis and investigation of the underlying pathophysiology of reversible posterior leukoencephalopathy syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006287      PMCID: PMC7974732     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome.

Authors:  J M Provenzale; J R Petrella; L C Cruz; J C Wong; S Engelter; D P Barboriak
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

3.  Widespread cerebral ischaemia treated with nimodipine in a patient with eclampsia.

Authors:  E H Horn; M Filshie; R W Kerslake; T Jaspan; B S Worthington; P C Rubin
Journal:  BMJ       Date:  1990-10-06

4.  Quantitative proton MR spectroscopic imaging of the human brain.

Authors:  B J Soher; P C van Zijl; J H Duyn; P B Barker
Journal:  Magn Reson Med       Date:  1996-03       Impact factor: 4.668

5.  The reversible posterior cerebral edema syndrome.

Authors:  W P Dillon; H Rowley
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

6.  CT and angiographic correlation of severe neurological disease in toxemia of pregnancy.

Authors:  L K Lewis; D B Hinshaw; A D Will; A N Hasso; J R Thompson
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

Review 7.  Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome.

Authors:  S G Pavlakis; Y Frank; R Chusid
Journal:  J Child Neurol       Date:  1999-05       Impact factor: 1.987

8.  Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions.

Authors:  R A Hauser; D M Lacey; M R Knight
Journal:  Arch Neurol       Date:  1988-10

9.  The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio.

Authors:  R E Brenner; P M Munro; S C Williams; J D Bell; G J Barker; C P Hawkins; D N Landon; W I McDonald
Journal:  Magn Reson Med       Date:  1993-06       Impact factor: 4.668

10.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types.

Authors:  J Urenjak; S R Williams; D G Gadian; M Noble
Journal:  J Neurosci       Date:  1993-03       Impact factor: 6.167

View more
  13 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

2.  Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging.

Authors:  Lauren M Brubaker; J Keith Smith; Yueh Z Lee; Weili Lin; Mauricio Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 3.  [Posterior reversible encephalopathy syndrome].

Authors:  D Staykov; S Schwab
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

Review 4.  Posterior reversible encephalopathy syndrome in children with kidney disease.

Authors:  Cristina Gavrilovici; Ingrith Miron; Luminiţa Voroneanu; Silvia Bădărau; Magdalena Stârcea
Journal:  Int Urol Nephrol       Date:  2017-08-23       Impact factor: 2.370

5.  Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review.

Authors:  Lei Zhang; Jian Xu
Journal:  Am J Clin Exp Immunol       Date:  2018-02-05

Review 6.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

7.  Leukoencephalopathy due to oral methotrexate.

Authors:  I González-Suárez; M J Aguilar-Amat; M Trigueros; A M Borobia; A Cruz; J Arpa
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

8.  Posterior reversible encephalopathy syndrome in the pediatric renal population.

Authors:  Ali Mirza Onder; Robert Lopez; Uygar Teomete; Denise Francoeur; Rita Bhatia; Obioma Knowbi; Rana Hizaji; Jayanthi Chandar; Carolyn Abitbol; Gaston Zilleruelo
Journal:  Pediatr Nephrol       Date:  2007-08-11       Impact factor: 3.714

9.  Clinical and radiological spectrum of posterior reversible encephalopathy syndrome.

Authors:  Sang-Duk Yoon; Byung-Moon Cho; Sae-Moon Oh; Se-Hyuck Park; In-Bock Jang; Jong-Young Lee
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2013-09-30

10.  Posterior reversible encephalopathy syndrome in a child with autoimmune lymphoproliferative syndrome: Case report and review of literature.

Authors:  Vaishnavi Chandramohan; Vinoth Ponnurangam Nagarajan; Muthamil Selvan Sathyamoorthi; Sathish Kumar; Chitrambalam Shanmugasundaram; Gokulakrishnan Periakaruppan; Julius Xavier Scott
Journal:  J Pediatr Neurosci       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.